 |
|
| Type | Public KK (TYO: 4568) |
|---|---|
| Founded | 2005 (by merger) |
| Headquarters |  Tokyo, Japan |
| Key people | Kiyoshi Morita, Chairman Takashi Shoda, President & CEO |
| Industry | Pharmaceutical |
| Products | Pharmaceutical products |
| Revenue | ▲ ¥ 880,120 million JPY (FY 2007) |
| Net income | ▲ ¥ 97,660 million JPY (FY 2007) |
| Employees | 15,349 (2008) |
| Website | www.daiichisankyo.com |
Daiichi Sankyo Co., Ltd. (第一三共株式会社 Daiichi Sankyō Kabushiki-kaisha, TYO: 4568) is a Japan-based major pharmaceutical company, which ranks number 22 in the world in sales[1].
Contents |
History
Daiichi Sankyo was established in 2005 through the merger of Sankyo Co., Ltd. (三共株式会社 Sankyō Kabushiki Kaisha) and Daiichi Pharmaceutical Co., Ltd. (第一製薬株式会社 Daiichi Seiyaku Kabushiki Kaisha), which were century-old pharmaceutical companies based in Japan.
Acquisitions
In 2006, Daiichi Sankyo acquired Zepharma, the OTC drugs unit of Astellas Pharma.
On June 10, 2008, Daiichi Sankyo agreed to take a majority (35%) stake in Indian generic drug maker Ranbaxy, with a deal valued at about $4.6 billion. Ranbaxy's Malvinder Singh will remain CEO after the transaction.[2][3]
In June 2008, the company expressed intent to acquire U3 Pharma, which would contribute a therapeutic anti-HER3 antibody to the company's anticancer portfolio.[4]
Products of Daiichi Sankyo Group
Sankyo
- Benicar (olmesartan medoxomil)
- Mevalotin (pravastatin)
- Loxonin (loxoprofen)
- Olmetec (olmesartan)
- Captopril
- Zantac (ranitidine)
- WelChol (colesevelam HCl)
Daiichi Pharmaceutical
- Cravit (levofloxacin)
- Evoxac (cevimeline)
- FloxinOtic (ofloxacin)
Pipeline Candidates
Select mid-stage and late-stage investigational candidates in Daiichi-Sankyo's pipeline include:
- CS-011 (rivoglitazone) - Type 2 Diabetes
- CS-1008 - Oncology
- CS-8635 - Cardiovascular disease
- CS-8958 - Influenza
- DU-176b - Venous thromboembolism
- Effient/Efient (Prasugrel) - Acute coronary syndrome and percutaneous coronary intervention
- SUN-11031 - Cachexia
References
- ^ http://pharmexec.findpharma.com/pharmexec/data/articlestandard//pharmexec/302008/531367/article.pdf
- ^ Daiichi to get 35% stake in Ranbaxy
- ^ The Brand Blog: Ranbaxy promoters to sell stake to Japan's Daiichi
- ^ staff (2008-06-15). "Daiichi Sankyo Intends to Purchase U3 Pharma for Roughly $236M" (print). Genetic Engineering & Biotechnology News (Mary Ann Liebert, Inc.): p. 8.
External links
 This article about a Japanese corporation- or company-related topic is a stub. You can help Wikipedia by expanding it. |
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
